Menu
Back to Journals » Vascular Health and Risk Management » Volume 5
Prevention of diabetes in hypertensive patients: Results and implications from the VALUE trial
Authors Zhou M, Schulman IH
Published 16 April 2009 Volume 2009:5 Pages 361—368
DOI https://doi.org/10.2147/VHRM.S4331
Review by Single anonymous peer review
Peer reviewer comments 3
Ming-Sheng Zhou, Ivonne Hernandez Schulman
Nephrology-Hypertension Section, Veterans Affairs Medical Center and Division of Nephrology and Hypertension and Vascular Biology institute, University of Miami Miller School of Medicine, Miami, FL, USA
Abstract: A growing number of experimental and clinical studies have provided evidence indicating that pharmacological blockade of the renin–angiotensin system (RAS) by either angiotensin-converting enzyme inhibitors or angiotensin type 1 receptor blockers reduces the incidence of new onset type 2 diabetes in subjects with hypertension and/or cardiovascular disease, independently of antihypertensive and cardiovascular protective effects. The beneficial effects of RAS inhibition on the development of diabetes have been largely attributed to improvements in peripheral insulin sensitivity and glucose metabolism. This review focuses on recent experimental and clinical evidence supporting the role of RAS inhibition in the reduction of new onset type 2 diabetes and the mechanisms that may be involved.
Keywords: renin–angiotensin system, antihypertensive, diabetes
© 2009 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.